Zhao D, Han X, Mu Q, Wu Y, Shan L, Su L
Nutr Metab (Lond). 2024; 21(1):52.
PMID: 39054540
PMC: 11270855.
DOI: 10.1186/s12986-024-00828-6.
Klobucar I, Degoricija V, Potocnjak I, Trbusic M, Pregartner G, Berghold A
Biomedicines. 2022; 10(7).
PMID: 35884971
PMC: 9313377.
DOI: 10.3390/biomedicines10071668.
Whyte M
JRSM Cardiovasc Dis. 2019; 8:2048004019869736.
PMID: 31448115
PMC: 6691666.
DOI: 10.1177/2048004019869736.
Tsuchida Y, Zhong J, Otsuka T, Dikalova A, Pastan I, Anantharamaiah G
Lab Invest. 2019; 99(8):1107-1116.
PMID: 31019291
PMC: 6658349.
DOI: 10.1038/s41374-019-0253-6.
Barochia A, Gordon E, Kaler M, Cuento R, Theard P, Figueroa D
J Lipid Res. 2017; 58(8):1713-1721.
PMID: 28655726
PMC: 5538292.
DOI: 10.1194/jlr.P077776.
The effects of exercise on the lipoprotein subclass profile: A meta-analysis of 10 interventions.
Sarzynski M, Burton J, Rankinen T, Blair S, Church T, Despres J
Atherosclerosis. 2015; 243(2):364-72.
PMID: 26520888
PMC: 4663138.
DOI: 10.1016/j.atherosclerosis.2015.10.018.
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Le N, Tomassini J, Tershakovec A, Neff D, Wilson P
J Am Heart Assoc. 2015; 4(10):e001675.
PMID: 26486166
PMC: 4845107.
DOI: 10.1161/JAHA.114.001675.
Metabolomics and partial least square discriminant analysis to predict history of myocardial infarction of self-claimed healthy subjects: validity and feasibility for clinical practice.
Mohamad N, Ismet R, Rofiee M, Bannur Z, Hennessy T, Selvaraj M
J Clin Bioinforma. 2015; 5:3.
PMID: 25806102
PMC: 4371619.
DOI: 10.1186/s13336-015-0018-4.
Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma.
Barochia A, Kaler M, Cuento R, Gordon E, Weir N, Sampson M
Am J Respir Crit Care Med. 2015; 191(9):990-1000.
PMID: 25692941
PMC: 4435459.
DOI: 10.1164/rccm.201411-1990OC.
CETP inhibitors and cardiovascular disease: Time to think again.
Miller N
F1000Res. 2014; 3:124.
PMID: 25187879
PMC: 4149245.
DOI: 10.12688/f1000research.4396.1.
HDL-targeted therapies: progress, failures and future.
Kingwell B, Chapman M, Kontush A, Miller N
Nat Rev Drug Discov. 2014; 13(6):445-64.
PMID: 24854407
DOI: 10.1038/nrd4279.
P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo.
Goffinet M, Tardy C, Boubekeur N, Cholez G, Bluteau A, Oniciu D
PLoS One. 2014; 9(4):e95807.
PMID: 24769858
PMC: 4000210.
DOI: 10.1371/journal.pone.0095807.
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Mora S, Glynn R, Ridker P
Circulation. 2013; 128(11):1189-97.
PMID: 24002795
PMC: 3807967.
DOI: 10.1161/CIRCULATIONAHA.113.002671.
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug....
Acharjee S, Boden W, Hartigan P, Teo K, Maron D, Sedlis S
J Am Coll Cardiol. 2013; 62(20):1826-33.
PMID: 23973693
PMC: 5661970.
DOI: 10.1016/j.jacc.2013.07.051.
Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.
Bardini G, Rotella C, Giannini S
Rev Diabet Stud. 2013; 9(2-3):82-93.
PMID: 23403704
PMC: 3700021.
DOI: 10.1900/RDS.2012.9.82.
Highlights of the year in JACC 2012.
DeMaria A, Bax J, Feld G, Greenberg B, Hall J, Hlatky M
J Am Coll Cardiol. 2013; 61(3):357-85.
PMID: 23328613
PMC: 3760511.
DOI: 10.1016/j.jacc.2012.12.002.
